郝伟,赵晨,胡思宁,贾海波,于波

• 1:哈尔滨医科大学附属第二医院心内科

摘要(Abstract)：

药物洗脱支架（DES）的诞生和不断优化已经大大提高了经皮冠状动脉介入治疗（PCI）的安全性和有效性，但随着病例复杂性的增加和DES的超适应证应用，术后再狭窄率正逐年上升。因此，当前DES时代下，支架内再狭窄（ISR）仍是临床上亟待解决的一大难题。本文将主要就DES置入后ISR发生发展的病理机制、组织病理学及治疗策略的最新研究成果及进展进行综述。

关键词(KeyWords)： 经皮冠状动脉介入治疗;支架内再狭窄;药物洗脱支架;药物涂层球囊

Abstract:

Keywords:

基金项目(Foundation): 黑龙江省自然科学基金研究团队项目（TD2020H001）

作者(Author): 郝伟,赵晨,胡思宁,贾海波,于波

参考文献(References)：

• [1]王紫斓，涂应锋，于波.支架置入术后再发急性冠状动脉综合征的研究进展[J].中国介入心脏病学杂志，2021,29(8):462-467. DOI:10.3969/j.issn.1004-8812.2021.08.007.
• [2] Byrne RA,Joner M,Kastrati A. Stent thrombosis and restenosis:what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014[J]. Eur Heart J,2015,36(47):3320-3331. DOI:10.1093/eurheartj/ehv511.
• [3] Dangas GD,Claessen BE,Caixeta A,et al. In-stent restenosis in the drug-eluting stent era[J]. J Am Coll Cardiol,2010,56(23):1897-1907. DOI:10.1016/j.jacc.2010.07.028.
• [4] Mehran R,Dangas G,Abizaid AS,et al. Angiographic patterns of in-stent restenosis:classification and implications for longterm outcome[J]. Circulation,1999,100(18):1872-1878. DOI:10.1161/01.cir.100.18.1872.
• [5] Shlofmitz E,Iantorno M,Waksman R. Restenosis of drugeluting stents:a new classification system based on disease mechanism to guide treatment and state-of-the-art review[J].Circ Cardiovasc Interv,2019,12(8):e007023. DOI:10.1161/CIRCINTERVENTIONS.118.007023.
• [6] Aoki J,Tanabe K. Mechanisms of drug-eluting stent restenosis[J].Cardiovasc Interv Ther,2021,36(1):23-29. DOI:10.1007/s12928-020-00734-7.
• [7] Wilson S,Mone P,Kansakar U,et al. Diabetes and restenosis[J].Cardiovasc Diabetol,2022,21(1):23. DOI:10.1186/s12933-022-01460-5.
• [8] Paramasivam G,Devasia T,Jayaram A,et al. In-stent restenosis of drug-eluting stents in patients with diabetes mellitus:clinical presentation,angiographic features,and outcomes[J].Anatol J Cardiol,2020,23(1):28-34. DOI:10.14744/AnatolJCardiol.2019.72916.
• [9] R?ber L,Mintz GS,Koskinas KC,et al. Clinical use o f intracoronary imaging. Part 1:guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions[J]. Eur Heart J,2018,39(35):3281-3300.DOI:10.1093/eurheartj/ehy285.
• [10] Yin D,Mintz GS,Song L,et al. In-stent restenosis characteristics and repeat stenting underexpansion:insights from optical coherence tomography[J]. EuroIntervention,2020,16(4):e335-e343. DOI:10.4244/EIJ-D-18-01191.
• [11] Hassan AK,Bergheanu SC,Stijnen T,et al. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis[J]. Eur Heart J,2010,31(10):1172-1180.DOI:10.1093/eurheartj/ehn553.
• [12] Lee SY,Im E,Hong SJ,et al. Severe acute stent malapposition after drug-eluting stent implantation:ef fects on long-term clinical outcomes[J]. J Am Heart Assoc,2019,8(13):e012800.DOI:10.1161/JAHA.119.012800.
• [13] Erdogan E,Bajaj R,Lansky A,et al. Intravascular imaging for guiding in-stent restenosis and stent thrombosis therapy[J]. J Am Heart Assoc,2022,11(22):e026492. DOI:10.1161/JAHA.122.026492.
• [14] O’Sullivan CJ,Stefanini GG,R?ber L,et al. Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug-eluting stents[J]. EuroIntervention,2014,9(9):1076-1084. DOI:10.4244/EIJV9I9A182.
• [15] Lee MS,Banka G. In-stent restenosis[J]. Interv Cardiol Clin,2016,5(2):211-220. DOI:10.1016/j.iccl.2015.12.006.
• [16] Cassese S,Byrne RA,Tada T,et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography[J]. Heart,2014,100(2):153-159. DOI:10.1136/heartjnl-2013-304933.
• [17] Camaj A,Giustino G,Claessen BE,et al. Effect o f s t e n t diameter in women undergoing percutaneous coronary intervention with early-and new-generation drug-eluting stents:from the WIN-DES collaboration[J]. Int J Cardiol,2019,287:59-61. DOI:10.1016/j.ijcard.2019.03.034.
• [18] Elezi S,Dibra A,Mehilli J,et al. Vessel size and outcome after coronary drug-eluting stent placement:results from a large cohort of patients treated with sirolimus-or paclitaxel-eluting stents[J].J Am Coll Cardiol,2006,48(7):1304-1309. DOI:10.1016/j.jacc.2006.05.068.
• [19] Lüscher TF,Steffel J,Eberli FR,et al. Drug-eluting stent and coronary thrombosis:biological mechanisms and clinical implications[J]. Circulation,2007,115(8):1051-1058.DOI:10.1161/CIRCULATIONAHA.106.675934.
• [20] Guedeney P,Claessen BE,Mehran R,et al. Coronary calcification and long-term outcomes according to drug-eluting stent generation[J]. JACC Cardiovasc Interv,2020,13(12):1417-1428. DOI:10.1016/j.jcin.2020.03.053.
• [21]李占鲁，黄翯.紫杉醇涂层球囊的应用现状和不足以及新一代药物涂层球囊的研究进展[J].中国介入心脏病学杂志，2022,30(4):299-302. DOI:10.3969/j.issn.1004-8812.2022.04.009.
• [22] Bangalore S,Toklu B,Patel N,et al. Newer-generation ultrathin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease[J].Circulation,2018,138(20):2216-2226. DOI:10.1161/CIRCULATIONAHA.118.034456.
• [23]阮月华，胡龙龙，杨人强.冠状动脉支架断裂的研究进展[J].中国介入心脏病学杂志，2020,28(5):286-290. DOI:10.3969/j.issn.1004-8812.2020.05.011.
• [24] Brancati MF,Burzotta F,Trani C,et al. Coronary stents and vascular response to implantation:literature review[J].Pragmat Obs Res,2017,8:137-148. DOI:10.2147/POR.S132439.
• [25] Torrado J,Buckley L,Durán A,et al. Restenosis,s t e n t thrombosis,and bleeding complications:navigating between scylla and charybdis[J]. J Am Coll Cardiol,2018,71(15):1676-1695. DOI:10.1016/j.jacc.2018.02.023.
• [26] Dejana E,Vestweber D. The role of VE-cadherin in vascular morphogenesis and permeability control[J]. Prog Mol Biol Transl Sci,2013,116:119-144. DOI:10.1016/B978-0-12-394311-8.00006-6.
• [27] Sakamoto A,Sato Y,Kawakami R,et al. Risk prediction of in-stent restenosis among patients with coronary drug-eluting stents:current clinical approaches and challenges[J]. Expert Rev Cardiovasc Ther,2021,19(9):801-816. DOI:10.1080/14779072.2021.1856657.
• [28] Nakamura D,Dohi T,Ishihara T,et al. Predictors and outcomes of neoatherosclerosis in patients with in-stent restenosis[J].EuroIntervention,2021,17(6):489-496. DOI:10.4244/EIJ-D-20-00539.
• [29] Siontis GC,Stefanini GG,Mavridis D,et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis:a network meta-analysis[J]. Lancet,2015,386(9994):655-664. DOI:10.1016/s0140-6736(15)60657-2.
• [30] Giacoppo D,Gargiulo G,Aruta P,et al. Treatment strategies for coronary in-stent restenosis:systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4 880 patients[J]. BMJ,2015,351:h5392. DOI:10.1136/bmj.h5392.
• [31] Neumann FJ,Sousa-Uva M,Ahlsson A,et al. 2018 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur Heart J,2019,40(2):87-165. DOI:10.1093/eurheartj/ehy394.
• [32] Lawton JS,Tamis-Holland JE, Bangalore S,et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization:a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines[J].J Am Coll Cardiol,2022,79(2):e21-e129. DOI:10.1016/j.jacc.2021.09.006.
• [33] Piccolo R,Bonaa KH,Efthimiou O,et al. Drug-eluting or baremetal stents for percutaneous coronary intervention:a systematic review and individual patient data meta-analysis of randomised clinical trials[J]. Lancet,2019,393(10190):2503-2510.DOI:10.1016/S0140-6736(19)30474-X.
• [34] Palmerini T,Benedetto U,Biondi-Zoccai G,et al. Long-term safety of drug-eluting and bare-metal stents:evidence from a comprehensive network meta-analysis[J]. J Am Coll Cardiol,2015,65(23):2496-2507. DOI:10.1016/j.jacc.2015.04.017.
• [35] Chevalier B,Moulichon R,Teiger E,et al. One-year results of the CRISTAL Trial,a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents[J]. J Interv Cardiol,2012,25(6):586-595. DOI:10.1111/j.1540-8183.2012.00769.x.
• [36] Stone GW,Ellis SG,O’Shaughnessy CD,et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within baremetal stents:the TAXUS V ISR randomized trial[J]. JAMA,2006,295(11):1253-1263. DOI:10.1001/jama.295.11.1253.
• [37] Giacoppo D,Alfonso F,Xu B,et al. Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis:a comprehensive,collaborative,individual patient data meta-analysis of 10 randomized clinical trials(DAEDALUS study)[J]. Eur Heart J,2020,41(38):3715-3728. DOI:10.1093/eurheartj/ehz594.
• [38] Mehilli J,Byrne RA,Tiroch K,et al. Randomized t r i a l of paclitaxel-versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents:the ISARDESIRE 2(intracoronary stenting and angiographic results:drug eluting stents for in-stent restenosis 2)study[J]. J Am Coll Cardiol,2010,55(24):2710-2716. DOI:10.1016/j.jacc.2010.02.009.
• [39] Alfonso F,Pérez-Vizcayno MJ,Dutary J,et al. Implantation of a drug-eluting stent with a dif ferent drug(switch strategy)in patients with drug-eluting stent restenosis. Results from a prospective multicenter study(RIBSⅢ[restenosis intra-stent:balloon angioplasty versus drug-eluting stent])[J]. JACC Cardiovasc Interv,2012,5(7):728-737. DOI:10.1016/j.jcin.2012.03.017.
• [40] Vyas A,Schweizer M,Malhotra A,et al. Meta-analysis of same versus dif ferent stent for drug-eluting stent restenosis[J].Am J Cardiol,2014,113(4):601-606. DOI:10.1016/j.amjcard.2013.10.041.
• [41] Xhepa E,Bresha J,Joner M,et al. Clinical outcomes by optical characteristics of neointima and treatment modality in patients with coronary in-stent restenosis[J]. EuroIntervention,2021,17(5):e388-e395. DOI:10.4244/EIJ-D-20-00662.
• [42]宋婷婷，陈韬，荆晶，等.药物涂层球囊在经皮冠状动脉介入治疗中的应用趋势——单中心5年数据分析[J].中国介入心脏病学杂志，2021,29(11):612-616. DOI:10.3969/j.issn.1004-8812.2021.11.003.
• [43] Giacoppo D,Alfonso F,Xu B,et al. Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis[J]. J Am Coll Cardiol,2020,75(21):2664-2678. DOI:10.1016/j.jacc.2020.04.006.
• [44] Verheye S,Vrolix M,Kumsars I,et al. The SABRE trial(sirolimus angioplasty balloon for coronary in-stent restenosis):angiographic results and 1-year clinical outcomes[J]. JACC Cardiovasc Interv,2017,10(20):2029-2037. DOI:10.1016/j.jcin.2017.06.021.
• [45] Cortese B,di Palma G,Latini RA,et al. Immediate and shortterm performance of a novel sirolimus-coated balloon during complex percutaneous coronary interventions. The fatebenefratelli sirolimus coated-balloon(FASICO)registry[J]. Cardiovasc Revasc Med,2017,18(7):487-491. DOI:10.1016/j.carrev.2017.03.025.
• [46] Rivero F,Bastante T,Cuesta J,et al. Treatment of instent restenosis with bioresorbable vascular scaffolds:optical coherence tomography insights[J]. Can J Cardiol,2015,31(3):255-259. DOI:10.1016/j.cjca.2014.11.017.
• [47] Alfonso F,Nuccio J,Cuevas C,et al. Treatment of coronary in-stent restenosis with bioabsorbable vascular scaf folds[J]. J Am Coll Cardiol,2014,63(25 Pt A):2875. DOI:10.1016/j.jacc.2013.05.107.
• [48] Grasso C,Attizzani GF,PatanéM,et al. First-in-human description of everolimus-eluting bioabsorbable vascular scaffold implantation for the treatment of drug-eluting stent failure:insights from optical coherence tomography[J]. Int J Cardiol,2013,168(4):4490-4491. DOI:10.1016/j.ijcard.2013.06.127.
• [49] Alfonso F,Cuesta J,Pérez-Vizcayno MJ,et al. Bioresorbable vascular scaf folds for patients with in-stent restenosis:the RIBSⅥstudy[J]. JACC Cardiovasc Interv,2017,10(18):1841-1851. DOI:10.1016/j.jcin.2017.06.064.
• [50] Negi SI,Torguson R,Gai J,et al. Intracoronary brachytherapy for recurrent drug-eluting stent failure[J]. JACC Cardiovasc I n t e r v, 2 0 1 6, 9(1 2):1 2 5 9-1 2 6 5. D O I:1 0. 1 0 1 6/j.jcin.2016.03.018.
• [51] Nakahama H,Jankowski M,Dixon SR,et al. Longt e r m outcome of brachytherapy treatment for coronary instent restenosis:ten-year follow-up[J]. Catheter Cardiovasc Interv,2019,93(4):E211-E216. DOI:10.1002/ccd.27866.
• [52] Meraj PM,Patel K,Patel A,et al. Northwell intracoronary brachytherapy for the treatment of recurrent drug eluting stent in-stent restenosis(NITDI study group)[J]. Catheter Cardiovasc Interv,2021,97(1):41-46. DOI:10.1002/ccd.28708.
• [53] Megaly M,Glogoza M,Xenogiannis I,et al. Outcomes of intravascular brachytherapy for recurrent drug-eluting in-stent restenosis[J]. Catheter Cardiovasc Interv,2021,97(1):32-38. DOI:10.1002/ccd.28716.
• [54] Varghese MJ,Bhatheja S,Baber U,et al. Intravascular brachytherapy for the management of repeated multimetallayered drug-eluting coronary stent restenosis[J]. Circ Cardiovasc Interv,2018,11(10):e006832. DOI:10.1161/CIRCINTERVENTIONS.118.006832.
• [55] Kearney KE,Wallner K,Kim M,et al. Intravascular coronary brachytherapy combined with a drug-coated balloon[J].Brachytherapy,2021,20(6):1276-1281. DOI:10.1016/j.brachy.2021.04.002.
• [56] Moustapha A,Assali AR,Sdringola S,et al. Percutaneous and surgical interventions for in-stent restenosis:long-term outcomes and ef fect of diabetes mellitus[J]. J Am Coll Cardiol,2001,37(7):1877-1882. DOI:10.1016/s0735-1097(01)01231-1.